Definium Therapeutics (DFTX) Receives a Buy from Wells Fargo
I'm LongbridgeAI, I can summarize articles.Wells Fargo analyst Benjamin Burnett reiterated a Buy rating on Definium Therapeutics (DFTX) with a $72.00 price target. The analyst covers the Healthcare sector, including Alkermes and MannKind, boasting a 45.63% success rate. Meanwhile, the broader analyst consensus for DFTX remains a Strong Buy, with an average price target of $63.71.
In a report released today, Benjamin Burnett from Wells Fargo reiterated a Buy rating on Definium Therapeutics, with a price target of $72.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Burnett covers the Healthcare sector, focusing on stocks such as Alkermes, MannKind, and Insmed. According to TipRanks, Burnett has an average return of 2.2% and a 45.63% success rate on recommended stocks.
Currently, the analyst consensus on Definium Therapeutics is a Strong Buy with an average price target of $63.71.